Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Cash (2023 - 2026)

CG Oncology posted quarterly Change in Cash of $1.2 million for Q1 2026, up 100.56% year-on-year from $603307.0 in Q1 2025, and up 109.56% on a QoQ basis from -$12.7 million in Q4 2025.

CG Oncology (CGON) has 4 years of Change in Cash data on file, last reported at $1.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash rose 100.56% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$7.8 million (up 78.41% YoY), and the FY2025 full-year result was -$224.6 million, down 190.26% from the prior year.
  • Change in Cash for Q1 2026 stood at $1.2 million, up from -$12.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $213.7 million in Q4 2024 and bottomed at -$215.6 million in Q1 2025.
  • The 4-year median for Change in Cash is -$2.0 million (2023), against an average of -$4.2 million.
  • The widest annual swing landed in 2024, when Change in Cash soared 10745.59%; it then slumped 411.55% in 2025.
  • A 4-year view of Change in Cash shows it stood at -$2.0 million in 2023, then jumped by 10745.59% to $213.7 million in 2024, then sank by 105.92% to -$12.7 million in 2025, then soared by 109.56% to $1.2 million in 2026.
  • The last three Change in Cash figures came in at $1.2 million (Q1 2026), -$12.7 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 CG Oncology 5.01 Bn 5.01 Bn -1.88 Mn 1.21 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.21 Mn
Dec 31, 2025 -12.66 Mn
Sep 30, 2025 30.52 Mn
Jun 30, 2025 -26.85 Mn
Mar 31, 2025 -215.60 Mn
Dec 31, 2024 213.66 Mn
Sep 30, 2024 18.25 Mn
Jun 30, 2024 -52.31 Mn
Mar 31, 2024 69.20 Mn
Dec 31, 2023 -2.01 Mn
Sep 30, 2023 -67.77 Mn
Jun 30, 2023 77.35 Mn
Mar 31, 2023 -87.45 Mn